Premium
Protective efficacy evaluation induced by recombinant protein LHD‐Sj23‐GST of Schistosoma japonicum emulsified with three different adjuvants
Author(s) -
ZHU Z.,
FU Z.,
ZHANG M.,
HAN Y.,
HONG Y.,
LI D.,
ZHAO Z.,
SHI Y.,
LI X.,
LIN J.
Publication year - 2012
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/j.1365-3024.2012.01357.x
Subject(s) - schistosoma japonicum , recombinant dna , adjuvant , schistosomiasis japonica , schistosomiasis , biology , antibody , immunology , antigen , virology , gene , helminths , biochemistry
Summary As a complement to chemotherapy and other control approaches, the development of an effective vaccine is necessary to combat Schistosomiasis japonica that remains a serious public health problem in China. In the present study, mice were vaccinated with purified recombinant protein LHD‐Sj23‐GST (large hydrophilic domain of 23 kDa antigen of S. japonicum fused with Sj26GST) emulsified with Freund’s adjuvant (FA), Montanide ISA 206 and Montanide ISA 70M and challenged with cercariae, the protective efficacy induced by the recombinant protein was evaluated, and the LHD‐Sj23‐GST‐specific IgG and its subtypes were determined. The result revealed that a significant worm burden reduction (58.8%, 26.3% and 54.3%; P < 0.05) was obtained in mice vaccinated with LHD‐Sj23‐GST emulsified with three different adjuvants compared to those mice treated with respective adjuvant only. ELISA test suggested that the high‐level production of LHD‐Sj23‐GST‐specific IgG1, IgG2a and IgG3 antibodies may participate in protecting against schistosome infection.